Table 2.

Characteristics of patients with clinical benefit

Pts with clinical benefit on bicalutamideAR%ER%PgR%HER2Site of testingSite of metastasesPrior therapy LABC/MBCDOR on prior therapy, wksDOR on bicalutamide, wks
#3>8000−/+PBreast LN1NR25
#4>9000NegPLN Bone115835
#5>5000NegPLN Bone11543+

Abbreviations: DOR, duration of response; GI, gastrointestinal; LABC, locally advanced breast cancer; LN, lymph node; Met, metastasis; NA, not applicable; NR, no response; P, primary tumor.